Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

J.A. Dormandy; B. Charbonnel; D.J. Eckland; E. Erdmann; M. Massi-Benedetti; I.K. Moules; A.M. Skene; M.H. Tan; P.J. Lefebvre; G.D. Murray; E. Standl; R.G. Wilcox

doi:10.1016/S0140-6736(05)67528-9

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. Erdmann, M. Massi-Benedetti, I.K. Moules, A.M. Skene, M.H. Tan, P.J. Lefebvre, G.D. Murray, E. Standl, R.G. Wilcox

VU University medical center

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1279-1289
Journal	Lancet
Volume	366
Issue number	9493
DOIs	https://doi.org/10.1016/S0140-6736(05)67528-9
Publication status	Published - 2005

Access to Document

10.1016/S0140-6736(05)67528-9

Embargoed Document

187968
Final published version, 165 KB

Cite this

Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefebvre, P. J., Murray, G. D., Standl, E., & Wilcox, R. G. (2005). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 366(9493), 1279-1289. https://doi.org/10.1016/S0140-6736(05)67528-9

@article{0b08fdbc34424fb0a51821de2a7d0eea,

title = "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial",

author = "J.A. Dormandy and B. Charbonnel and D.J. Eckland and E. Erdmann and M. Massi-Benedetti and I.K. Moules and A.M. Skene and M.H. Tan and P.J. Lefebvre and G.D. Murray and E. Standl and R.G. Wilcox",

year = "2005",

doi = "10.1016/S0140-6736(05)67528-9",

language = "English",

volume = "366",

pages = "1279--1289",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "9493",

}

Dormandy, JA, Charbonnel, B, Eckland, DJ, Erdmann, E, Massi-Benedetti, M, Moules, IK, Skene, AM, Tan, MH, Lefebvre, PJ, Murray, GD, Standl, E & Wilcox, RG 2005, 'Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial', Lancet, vol. 366, no. 9493, pp. 1279-1289. https://doi.org/10.1016/S0140-6736(05)67528-9

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. / Dormandy, J.A.; Charbonnel, B.; Eckland, D.J. et al.

In: Lancet, Vol. 366, No. 9493, 2005, p. 1279-1289.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

AU - Dormandy, J.A.

AU - Charbonnel, B.

AU - Eckland, D.J.

AU - Erdmann, E.

AU - Massi-Benedetti, M.

AU - Moules, I.K.

AU - Skene, A.M.

AU - Tan, M.H.

AU - Lefebvre, P.J.

AU - Murray, G.D.

AU - Standl, E.

AU - Wilcox, R.G.

PY - 2005

Y1 - 2005

U2 - 10.1016/S0140-6736(05)67528-9

DO - 10.1016/S0140-6736(05)67528-9

M3 - Article

VL - 366

SP - 1279

EP - 1289

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9493

ER -